SEMA4A and breast carcinoma: Our observation of breast cancer-specific downregulation of both NRP-1 and SEMA4A in PBMCs is in agreement with the reports of Delgoffe et al. that the interaction of these molecules on circulating PBMCs may not play a role in tumor immune evasion but rather has a protective characteristic.